MBX-8025

1 stories · following the connections

Business

CymaBay Therapeutics Announces Positive Results from its Pilot Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia

By Nasdaq OMXMar 17, 2016, 8:01 PM UTC